NYSE - Nasdaq Real Time Price USD
Zoetis Inc. (ZTS)
79.72 +1.45 (+1.85%)
At close: October 30 at 4:00:03 PM EDT
79.29 -0.43 (-0.54%)
After hours: October 30 at 7:57:55 PM EDT
Trade Zoetis on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for ZTS
What's happening with ZTS?
Powered by Yahoo ScoutZoetis enters its November 5 earnings release with mixed signals. New FDA approval for Convenia RTU expands its canine portfolio, while weaker pet-care demand, price pressure, and lower earnings expectations remain central concerns. The company’s valuation is below historical and peer levels, but the discount reflects slower growth and execution risks.
Powered by Yahoo Scout
- Previous Close
78.27 - Open
79.84 - Bid 79.54 x 20000
- Ask 79.65 x 10000
- Day's Range
79.21 - 80.60 - 52 Week Range
68.77 - 144.83 - Volume
4,117,231 - Avg. Volume
4,982,251 - Market Cap (intraday)
32.942B - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
13.11 - EPS (TTM)
6.08 - Earnings Date Nov 5, 2026
- Forward Dividend & Yield 2.12 (2.66%)
- 1y Target Est
88.38 - Morningstar Rating Rating available with Stock Picks access
Recent News
View More
Performance Overview
Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
ZTS
35.21%
S&P 500 (^GSPC)
10.73%
1-Year Return
ZTS
43.23%
S&P 500 (^GSPC)
11.11%
3-Year Return
ZTS
46.74%
S&P 500 (^GSPC)
81.91%
5-Year Return
ZTS
60.78%
S&P 500 (^GSPC)
64.59%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 10/30/2026
Market Cap
32.94B
Enterprise Value
40.51B
Trailing P/E
13.11
Forward P/E
13.35
PEG Ratio (current)
1.49
Price/Sales (ttm)
3.61
Price/Book (mrq)
10.49
Enterprise Value/Revenue
4.26
Enterprise Value/EBITDA
10.43
Financial Highlights
Profitability and Income Statement
Profit Margin
27.68%
Return on Assets (ttm)
15.35%
Return on Equity (ttm)
64.91%
Revenue (ttm)
9.53B
Net Income Avi to Common (ttm)
2.64B
Diluted EPS (ttm)
6.08
Balance Sheet and Cash Flow
Total Cash (mrq)
1.68B
Total Debt/Equity (mrq)
294.00%
Levered Free Cash Flow (ttm)
2.02B
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreZoetis: Reducing Our Valuation to Reflect Greater Competitive Pressure, but Moat Remains Intact
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 30% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 70% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Zoetis: Reducing Our Valuation to Reflect Greater Competitive Pressure, but Moat Remains Intact
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 30% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 70% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Lowering our earnings estimates
Zoetis Inc., a 2013 spin-off from Pfizer, focuses on the development, manufacture, and commercialization of animal health vaccines and medicines, including parasiticides, anti-infectives, and medicated feed additives. The company develops products for both livestock and companion animals and distributes its products globally. Zoetis is a component of the S&P 500 and has roughly 14,500 employees.
The major indices are mixed at midday, but the mood is generally upbeat
The major indices are mixed at midday, but the mood is generally upbeat following the release of additional tame inflation data this morning (this time in the form of wholesale prices). Earnings continue to hit the tape and individual stocks are responding in kind. Crude oil is at $82 per barrel. The yield on the 10-year note is at 4.63%.